The current financial burden The cost of providing 100% of obese Americans with GLP-1 medications would surpass $1 trillion a year, even with drug rebates
Study Limitations and Future Research The authors noted several limitations, including that most study participants were male and a large proportion were white
In particular, reduced GST activity as compared to control subjects was described in all brain areas and ventricular CSF in postmortem AD patients, suggesting a role of these enzymes in the pathogenesis of the disease 51
Ongoing support: Patients can continue with provider-guided care, nutrition guidance, and optional precision wellness testing to support long-term success
[DOI] [PMC free article] [PubMed] [Google Scholar] 61.Ekbom A, Helmick C, Zack M, Adami HO